Abstract: Type 1 diabetes is an immune-mediated disorder that affects insulin-producing pancreatic beta cells. Destruction of beta cells progressively decreases endogenous insulin secretion. The disease remains subclinical for the initial months to years, but when insulin production achieves a critical level and glucose homeostasis is no longer possible, diabetes becomes clinically evident. Itis long known that at diagnosis, patients still preserve approximately 15 to 20% of their original beta cell mass. Attempts to preserve this residual pancreatic function have been described for the past 20 years. Numerous immunosuppressive and immunomodulating drugs have been investigated both prophylactically and at diagnosis. While several placebo-controlled trials have successfully shown a lesser degree of beta cell destruction in immunosuppressed patients, none were able to effectively increase pancreatic function or to substantially decrease exogenous insulin injections. In the past 10 years, autologous hematopoietic stem cell transplantation (AHSCT) has been investigated as a possible immunoablative approach to cease beta cell destruction early after diagnosis of type 1 diabetes. Studies have demonstrated that AHSCT was able to increase endogenous pancreatic function, measured through C-peptide levels, for at least 48 months (4 years) after transplantation. Furthermore, most patients remained insulin-free, transiently or continuously, for a median duration of 44 (range 6 -132) months after AHSCT. Although improvements in the protocol are still required to increase duration of the transplantmediated immunological effects, AHSCT is so far the most effective intervention to improve pancreatic function and glycemic control of type 1diabetes patients. Disclosure of Interest: None declared. Abstract: Acute lymphoblastic leukemia (ALL) is a heterogeneous disease characterized by several genetic subgroups. The good prognosis subgroups (ETV6-RUNX1 translocation and high hyprediploid ALLs) are common in children but rare in adults. The talk will focus on recent discoveries of molecular subtypes of ALL that are relevant to adults and may be amenable to targeted therapies. The first group is kinase driven ALLs, more commonly known as "Philadelphia like" or "BCR-ABL like" ALLs. This group can be generally divided into two large subgroups. One that is driven by ABL signaling pathway and should therefore be sensitive to ABL inhibitors, and the other that is driven by the JAK-STAT pathway. The relevance of commercially available JAK inhibitors for treatment of these JAK-STAT leukemias is unknown. The precise diagnostic approach for the identification of kinase driven leukemias is undecided yet. Importantly a significant fraction to T-ALLs that is dependent on IL7 signaling may also be sensitive to JAK inhibitors. Another therapeutically relevant discovery is the distinction between early pre-B ALLs and ALLs that depend on signaling from the pre-B cell receptors (pre-BCR). The second group, whose frequency in adults is currently unclear, is characterized by high expression of BCL6 and by sensitivity to Dasatinib and possibly also to other inhibitors of BCR. Thus new discoveries of molecular subtypes of ALL are likely to expand the role of kinase inhibitors in the treatment of ALL. Disclosure of Interest: None declared.
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Allogeneic stem cell transplantation (Allo-SCT) for Acute Lymphoblastic Leukemia (ALL) in adult patients -are we doing better? A. Nagler 1,* on behalf of ALWP 1 Division of Hematology, Chaim Sheba Medical Center Tel Has homer, Israel Abstract: Acute lymphoblastic leukemia (ALL) is a heterogenic neoplasm of the lymphocyte precursor cells. Among adult patients (pts) it is a relatively rare malignancy with an historical curability rate of around 30% at 5 years. Allo-SCT is the treatment of choice for adult pts with ALL after first relapse, and is also recommended for high-risk pts in first CR. Recent developments including minimal residual disease (MRD) evaluation and monitoring is emerging as the most important prognostic factor in determining which of the pts, especially those with standard risk, should be referred to allo-SCT. Tyrosine kinase inhibitor (TKI) therapy allows a much higher proportion of ph+ ALL pts to attain remission and proceed to allo-SCT with improved results. Post-transplant TKI maintenance therapy may also provide survival benefit. Reducedintensity conditioning (RIC) regimens and the availability of unrelated and recently alternative donors for allo-SCT, are reasonable options for pts who would otherwise be ineligible for transplant due to age, co-morbidities, or lack of an HLA matched sibling donor. Novel compounds like the Bi-specific T-cell engagers (BiTEs) antibody-Blinatumomab and the chimeric antigen receptor (CAR) CD19 T cells pre-or post allo-SCT may further improve results. Previous transplantation studies mainly for AML and MDS indicated improvement of allo-SCT outcome in recent years due to better supportive care, high resolution HLA typing and anti-fungal and viral prophylaxis, resulting in about 50% in transplant related mortality. However, paucity of data is available for allo-SCT in ALL. We therefore recently analyzed if results of allo-SCT from unrelated (UD) and Haploidentical donors (HD) improved over time and tried to identify prognostic factors using the data registered with the ALWP of the EBMT. Specifically, we analyzed 2178 adult pts with ALL that underwent allo-SCT from UD in the various EBMT centers and reported to the ALWP between 1993 to 2012. Transplantation outcome for 3 subsequent periods: 1993-2002 vs 2003-2007 vs 2008-2012 , respectively in various age groups were compared. Our study indicate that outcome of allo-SCT from UD for adults with ALL in CR improved significantly over time with an overall survival rate reaching 65%. The improvement was mainly related to reduced relapse risk and was particularly prominent for 36-55 years old pts and those with Ph+ disease. As for allo-SCT from HD, in order to investigate the outcome of unmanipulated haploidentical SCT (haplo) for ALL we performed a retrospective analysis of 264 adult pts transplanted in EBMT centers from 2007 to 2014. The study results indicated that unmanipulated haplo-SCT seems to be an effective mode of therapy for adults pts with ALL with 49% OS and 45% LFS at 2 years post transplantation in pts in first CR and impressive 39% GRFS. Disease status at transplant and use of PTCy were the main factors affecting outcomes. In 2 additional recent studies we analyzed Thiotepa based allo-SCT for adults with ALL and compared non T depleted Haplo-SCT to unrelated transplants in adult pts with ALL not in remission. Overall we may conclude that "We are doing better" thanks to improve in transplantation strategies, donor availability, novel compounds and conditioning, pre-and post-transplantation, targeted therapies as well as MRD monitoring and the availability of TKIs for ph+ ALL. Future means to decrease transplant related toxicity and relapse are in need in order to further improve outcomes. Abstract: Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is characterized by expression of oncogenic fusion product BCR-ABL1, resulting from reciprocal translocation between chromosomes 9 and 22 [t(9;22)(q34; q11.2)]. Historically, under the sole chemotherapy, it had a very poor prognosis, with a median survival of 8 months. The incorporation of BCR-ABL1 tyrosine kinase inhibitors (TKIs) into chemotherapy has significantly improved its outcomes. The best results have been obtained with immediate TKIs incorporation at Ph+ ALL recognition and with prolonged and continuous exposure of TKIs. Allogeneic stem cell transplantation (HSCT), either in the pre-TKI or post-TKI era, offers significant improvement in OS and is recognized as the mainstay of Ph+ALL treatment. With TKIs, higher remission rates were achieved, thus allowing more patients to proceed with HSCT. Some studies reported the lack of survival benefit with imatinib addition to chemotherapy in the absence of HSCT. However, the indispensability of HSCT was scrutinized following data from pediatric Ph+ ALL patients. Moreover, second-generation TKIs, as dasatinib that inhibits SRC kinases, are more potent than imatinib. Ravandi et al reported that patients receiving dasatinib with induction therapy chemotherapy, continuously throughout consolidation and then during maintenance therapy, obtained excellent CR and cytogenetic response, while in CR1 patients, no outcome differences were observed in patients whether or not they have undergone HSCT. Recently, in the GRAAPH-2005 study, the 3-year survival was similar between patients who underwent a HSCT and those who received an autograft. Finally, the predictive value of minimal residual disease by real-time quantitative polymerase chain reaction and by multiparameter flow cytometry may identify different prognostic groups in CR1 patients, for whom the best consolidation strategies remain to be validated. All these very recent advances have opened the debate: should all Ph+ALL patients be considered to have a devastating disease? Disclosure of Interest: None declared. We generated and propagated CAR + CIK cells with the purpose of optimizing cell expansion and, at the same time, minimizing cell manipulation and specific selection. We obtained around 60% stable expression of two distinct 3rd generation CARs, specific for the acute myelogenous leukemia (AML) CD123 + or acute lymphoblastic leukemia (ALL) CD19 + blasts. The procedure minimally affected the phenotype of CIK cells and was effective in inducing T cell expansion, with a fold increase suitable for future translation into adoptive cell therapy clinical protocols. Modified CIK cells displayed stable expression of CD123.CAR or CD19.CAR, persistence of a subset with memory phenotype and efficient lysis of leukemic cell lines and primary blasts. Specific target recognition by the CAR elicited cytokine secretion and cell proliferation. Adoptive transfer of CD123. CAR or CD19.CAR CIK cells exhibited control of AML and ALL in mice, respectively. Notably, no evidence of integration enrichment near cancer-related genes neither presence of transposase enzyme at the end of differentiation was detected, assuring the safety profile of SB system. This easy clinical-grade method of expansion coupled with SB-mediated gene transfer, in the absence of any process of selection, has the chance to improve the range of applications of adoptive cell therapy protocol to control early relapse in high-risk leukemic patients. Disclosure of Interest: None declared. 6 cells/kg recipient ideal body weight). This portion of the study has been completed and 1x10
6 cells iCasp9-modified T-cells/kg was the RD for the phase II portion of the study. Overall, considering both the phase I and II portions of the study, 40 patients have already been enrolled in the trial and, remarkably, none of them died due to transplant-related complications. In all patients, iCasp9-modified T-cells engrafted, expanded and persisted over time, being still detectable even in patients with a follow-up longer than 1 year. These cells contribute to accelerate the recovery of adaptive immunity, with improved clinical outcome. A more detailed analysis of the impact of iCasp9-modified T-cells on both patient's outcomes and immune recovery will be presented during the meeting. Disclosure of Interest: None declared. In In Italy, a randomized phase II neo-adjuvant study of standard versus high dose chemotherapy has recently been initiated. It focusses on triple-negative tumors and it compares a standard 3 rd generation regimen (4x epirubicin/cyclophosphamide -4x Docetaxel) with 4x epirubicin/docetaxel followed by high-dose therapy with epirubicin, cyclophosphamide and thiotepa. In the Netherlands, a small multicentre phase III study of neoadjuvant high-dose chemotherapy has recently completed patient accrual. It targets stage II or III triple-negative tumours with evidence of a homologous recombination defect (HRD). Such tumours may be hypersensitive to DNA crosslinking agents. Approximately 120 patients with HRD were randomized to receive either 6 courses of conventional chemotherapy or 4 conventional courses followed by tandem intensive therapy consisting of cyclophosphamide, thiotepa and carboplatin. This study will be followed in 2016 by an international controlled trial in the (neo) adjuvant setting, the SUBITO trial, which will employ the same methods. A single-institution Dutch study, employing the same regimens, investigates the efficacy in oligometastatic breast cancers with evidence of HRD. The Dutch and Italian controlled studies in triple-negative disease should either confirm or refute the hypothesis that high-dose chemotherapy with PBPC-support could improve the outlook for patients with triple-negative HRBC. If positive, high-dose therapy with modern agents and modern supportive care should be re-evaluated in other breast cancer subtypes as well. Abstract: Mantle cell lymphoma (MCL) is a heterogeneous disease with a median age at diagnosis of between 60 and 70 years. In younger patients, the introduction of more aggressive induction chemotherapy with high-dose cytarabine and rituximab, with or without autologous stem cell transplantation (ASCT), significantly improves the prognosis. However, it is not clear whether consolidation therapy with ASCT is necessary in all younger patients with newly diagnosed MCL. The long term follow-up results of a phase II study in patients treated with rituximab, hyper-fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with methotrexate and cytarabine (R-HCVAD/ MA), without ASCT, has been recently reported. 1 R-HCVAD/MA showed sustained efficacy, with a median overall survival (OS) exceeding 10 years. For the patients aged ≤ 65 years who are usually candidates for ASCT consolidation, the median failure free survival (FFS) was 6.5 years. In this subgroup of patients, the median OS was 13.4 years, and failure free survival (FFS) plateaued after 10 years. In addition, freedom from disease recurrence of nearly 15 years in almost 30% of the younger patients ( ≤ 65 years) was observed. These results seem to be similar for those obtained in patients managed with ASCT in a similar patient population. However, these excellent results have not been confirmed in multicenter studies or compared with ASCT-based therapy in phase III trials. In addition, new targeted agents, i.e. bortezomib, lenalidomide and ibrutinib, can be incorporated into frontline therapy combinations and maintenance strategies in younger patients in the near future. The results of recent trials show that non-transplant therapy with these new drugs can lead to prolonged remissions in previously untreated and relapsed/refractory patients.
2,3 These therapies are highly effective and less toxic than standard high-dose chemotherapy with ASCT consolidation. Bortezomib is the first proteasome inhibitor which has been approved recently for first-line treatment, both in the US and the EU. The approval was based on the results of a phase III clinical trial comparing VR-CAP (bortezomib plus rituximab, cyclophosphamide, doxorubicin and prednisone) with the R-CHOP regimen.
2 Bortezomib, when used in the VR-CAP regimen, has demonstrated improved outcomes for newly-diagnosed patients with MCL, 65 years old and older. Another very effective first-line therapy in MCL is that of lenalidomide combined with rituximab. 3 In a group of patients with a median age of 65 years, the overall response rate was 92% and the complete response rate was 64%. Two-year progressionfree survival was 85% and two-year overall survival 97%. Several trials have demonstrated that patients with a high MCL International Prognostic Index (MIPI) score were more likely to progress and die after ASCT consolidation compared with low-intermediate risk patients. For those patients, novel therapeutic strategies based on targeted drugs are urgently needed. In addition, patients achieving MRD-negative remissions after induction with alternating R-CHOP and R-DHAP therapy achieve significantly longer PFS and OS than patients with an MRD-positive status. For those MRD negative patients, ASCT consolidation is probably not necessary. Finally, a maintenance approach based on rituximab or other targeted drugs has been found to offer effective management in older patients. It is possible that novel therapies and maintenance strategies can replace ASCT in younger population of patients.
and IMiDs have a synergistic effect and in consequence this combination would be preferable. There are ongoing trials exploring the potential benefit of adding a MoAb (i.e., the anti-CD38 daratumumab) to the "classic" triple regimens. The number of induction cycles ranges between 3 and 6. The author of the present abstract prefers 6 cycles when using bortezomib in combination with IMiDs in order to maximize its potential synergy. Patients with high-risk cytogenetics have an inferior outcome even when treated with novel agents. In this subset, tandem ASCT seems to be of benefit. The concept of post-transplant consolidation consists of the administration of additional chemotherapy cycles, usually the ones used during the induction period, at full doses over a short period of time, usually between 2 and 4 months in order to further decrease the post-transplant tumour burden, including the evaluation of the minimal residual disease before and after consolidation. This promising approach is being increasingly explored in ongoing trials and will likely be established in clinical practice. The maintenance therapy consists of the administration of low-dose drugs over a long term periods ranging from 1 to 3 years or in some instances indefinitely until undue toxicity or disease progression. The aim of maintenance is to maintain a low-tumour burden and delay relapse. The best results have been reported with IMiDs, particularly with lenalidomide, although the issues of more resistant disease at relapse and the second primary malignancies have raised some concerns. The potential synergy between lenalidomide and proteasome inhibitors (i.e., ixazomib), as well as the efficacy of MoAbs, are being explored in current trials. Finally, the main goal of ASCT in MM is the achievement of a prolonged PFS and to try to increase the cure fraction (operational cure) and the will only be reached by a "Refined Total Therapy" approach including the best induction, consolidation and maintenance, incorporating the new available drugs. Disclosure of Interest: None declared. Abstract: Induction regimens incorporating thalidomide, lenalidomide, and/or bortezomib are now standard for newly diagnosed multiple myeloma (MM). Eligible patients may undergo high dose therapy with autologous stem cell transplantation (ASCT), which deepens and prolongs the therapeutic response and improves outcome, especially when integrated with novel agents. Consolidation/maintenance post ASCT not only upgrades but also deepens the response which translates into improved progression-free survival. Current approaches to management of newly diagnosed MM have significantly increased survival in MM. However, even patients who achieve a high quality and prolonged duration of response with initial therapy will ultimately relapse. In undertaking the relapse diagnostic evaluation, it is important to consider various factors that will influence treatment strategy. These include characteristics of the disease itself, response and duration of response to prior therapy including treatment related toxicities, eligibility for stem cell transplantation, and characteristics of the individual patient.
Patients are usually retreated with a two or three drugs combination which can include an immune modulatory drug (IMiD), a proteasome inhibitor, steroids and an alkylating agent. Monoclonal antibodies will soon be added to these combinations. Once in a state of new remission, one may consider transplantation and if not continuous treatment until the next progression. For patients transplant eligible, in contrast to the upfront setting in which the role of ASCT as consolidation of a 1st remission is well established, the role of high dose therapy with autologous or allogeneic stem cell transplantation has not been extensively studied in MM patients relapsing after primary therapy. Experts made recently the following consensus statements:
For salvage ASCT: 1. In transplant eligible patients relapsing after primary therapy that did not include an ASCT, ASCT as part of salvage therapy should be considered standard; 2. ASCT should be considered appropriate therapy for any patients relapsing after primary therapy that includes an ASCT with initial remission duration of more than 18 months; 3. ASCT can be used as a bridging strategy to allogeneic transplantation; 4. The role of post salvage ASCT maintenance needs to be explored in the context of well designed prospective trials that should include new agents such as monoclonal antibodies, IMiD and oral proteasome inhibitors; 5. ASCT consolidation should be explored as a strategy to develop novel conditioning regimens or post ASCT strategies in patients with short (less than 18 months remissions) after primary therapy; 6. Prospective randomized trials need to be performed to define the role of salvage ASCT in patients relapsing after primary therapy comparing to "best non ASCT" therapy. The expert committee also underscored the importance of collecting enough hematopoietic stem cells to perform two transplants early in the course of the disease. In regards to allogeneic hematopoietic stem cell transplantation (HCT), the expert committee agreed on the following consensus statements: However, even in these novel agents' era, high dose melphalan followed by stem cell support is still considered as a backbone in the treatment of transplant-candidate MM patients. As has been said, most of the recently developed novel agents have been approved for the treatment of MM patients at relapse, but they are already being used in the peri-trasplant situation in order to improve the results of this procedure. In this regards some trials have substituted bortezomib for carfilzomib in induction regimes before transplant, and it has been combined with lenalidomide +dexamethasone or with thalidomide+dexamethasone with or without cyclophosphamide, with a VGPR rate or better before transplant superior to 50%. Moreover, some of these trials included a consolidation phase after transplant with the same combination what clearly improved the responses. In a more optimistic approach, the Spanish MM group is currently enrolling patients in the "CESAR" trial in which transplanteligible smoldering MM patients with high risk of progression are being treated with KRD (Carfilzomib+Lenalidomide+dex-amethasone) as induction followed by ASCT, a consolidation with KRD and a maintenance phase, with the objective of achieving the cure of some of these patients. Probably a next step would be to incorporate MoAb to this cocktail of agents. Finally, some of these novel agents, are also being used in the maintenance setting. The main representative is ixazomib, a second generation proteasome inhibitor that on top of its excellent tolerability is of oral administration. As an example, this agent is being tested alone or in combination with lenalidomide and dexamethasone in some placebo-controlled trials. In summary, the recent approval of novel agents and mechanisms of action has increased treatment options for multiple myeloma patients. Although these innovations, are nowadays mainly focused on the relapsed situation, they are already being explored in the first line setting, and it is reasonable to think that in the near future very effective combinations including many of these agents as induction, consolidation and maintenance will be incorporated in the clinical practice. 
